Log in

BioCryst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BCRX)

$2.44
+0.04 (+1.66 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$2.37
Now: $2.45
$2.53
50-Day Range
$2.36
MA: $2.89
$3.22
52-Week Range
$2.35
Now: $2.45
$9.95
Volume664,002 shs
Average Volume1.77 million shs
Market Capitalization$270.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.65 million
Book Value$0.45 per share

Profitability

Net Income$-101,250,000.00
Net Margins-1,091.44%

Miscellaneous

Employees100
Market Cap$270.03 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.


BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.03. The biotechnology company earned $1.45 million during the quarter, compared to analyst estimates of $2.52 million. BioCryst Pharmaceuticals had a negative net margin of 1,091.44% and a negative return on equity of 371.33%. View BioCryst Pharmaceuticals' Earnings History.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for BioCryst Pharmaceuticals.

What price target have analysts set for BCRX?

6 brokers have issued 12 month price objectives for BioCryst Pharmaceuticals' shares. Their predictions range from $4.50 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $9.10 in the next year. This suggests a possible upside of 272.2% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.

What is the consensus analysts' recommendation for BioCryst Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/8/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to achievement of price target. We reiterate our Buy rating and our price target of $13 is based on the following risk-adjusted sum-of-the-parts NPV-DCF: $11.1 for oral HAE prophylactic treatment + $1.1 for oral liquid HAE acute treatment + $0.2 for peramivir + $0.4 in cash. We assume a discount rate of 13.5%." (5/22/2019)

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

Headlines about BCRX stock have trended negative on Sunday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for BioCryst Pharmaceuticals.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include El Pollo LoCo (LOCO), Idera Pharmaceuticals (IDRA), Inovio Pharmaceuticals (INO), Virtu Financial (VIRT), Advanced Micro Devices (AMD), La Jolla Pharmaceutical (LJPC), Alcoa (AA), Exelixis (EXEL), Sangamo Therapeutics (SGMO) and XOMA (XOMA).

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $2.45.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $270.03 million and generates $20.65 million in revenue each year. The biotechnology company earns $-101,250,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.View Additional Information About BioCryst Pharmaceuticals.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is http://www.biocryst.com/.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]


MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  388 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  750
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel